Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib, open lable trial of orally administered DUR-928 for the treatment of non-alcoholic steatohepatitis (NASH) patients

Trial Profile

A Phase Ib, open lable trial of orally administered DUR-928 for the treatment of non-alcoholic steatohepatitis (NASH) patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Larsucosterol (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Biomarker; Pharmacokinetics; Proof of concept
  • Sponsors DURECT Corporation

Most Recent Events

  • 26 Jun 2021 Results for further analysis of efficacy signals from this trial, presented at The International Liver Congress 2021
  • 23 Jun 2021 According to a DURECT Corporation media release, data from this study presented at the 2021 International Liver Conference (EASL).
  • 23 Jun 2021 Results published in the DURECT Corporation media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top